MY175935A - Method for activating helper t cell - Google Patents
Method for activating helper t cellInfo
- Publication number
- MY175935A MY175935A MYPI2015701777A MYPI2015701777A MY175935A MY 175935 A MY175935 A MY 175935A MY PI2015701777 A MYPI2015701777 A MY PI2015701777A MY PI2015701777 A MYPI2015701777 A MY PI2015701777A MY 175935 A MY175935 A MY 175935A
- Authority
- MY
- Malaysia
- Prior art keywords
- hla
- molecule
- activating helper
- cell
- drb1
- Prior art date
Links
- 230000003213 activating effect Effects 0.000 title abstract 3
- 210000002443 helper t lymphocyte Anatomy 0.000 title abstract 3
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 abstract 2
- 108010065026 HLA-DQB1 antigen Proteins 0.000 abstract 2
- 108010039343 HLA-DRB1 Chains Proteins 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 abstract 1
- 102210026621 HLA-DRB1*13 Human genes 0.000 abstract 1
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012274494 | 2012-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY175935A true MY175935A (en) | 2020-07-15 |
Family
ID=50978342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015701777A MY175935A (en) | 2012-12-17 | 2013-12-16 | Method for activating helper t cell |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9833493B2 (fr) |
| EP (1) | EP2933261B1 (fr) |
| JP (1) | JP6530192B2 (fr) |
| KR (1) | KR102158225B1 (fr) |
| CN (2) | CN104995203B (fr) |
| AR (1) | AR094026A1 (fr) |
| AU (1) | AU2013365067B2 (fr) |
| BR (1) | BR112015013697A2 (fr) |
| CA (1) | CA2892660C (fr) |
| EA (1) | EA201591168A1 (fr) |
| ES (1) | ES2805337T3 (fr) |
| HK (1) | HK1216755A1 (fr) |
| IL (1) | IL239056A0 (fr) |
| MX (1) | MX2015007745A (fr) |
| MY (1) | MY175935A (fr) |
| NZ (1) | NZ708990A (fr) |
| PH (1) | PH12015501361A1 (fr) |
| SG (2) | SG11201504530VA (fr) |
| TW (1) | TWI646970B (fr) |
| UA (1) | UA118962C2 (fr) |
| WO (1) | WO2014098012A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2378264T3 (es) | 2003-11-05 | 2012-04-10 | International Institute Of Cancer Immunology, Inc. | Péptido antigénico de unión a HLA-DR derivado de WT1 |
| CA2900087C (fr) | 2005-10-17 | 2024-02-13 | Sloan Kettering Institute For Cancer Research | Peptides de liaison wt1 hla de classe ii, compositions et methodes associees comprenant ces peptides |
| US9265816B2 (en) | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
| NZ578721A (en) | 2007-02-27 | 2012-04-27 | Int Inst Cancer Immunology Inc | Method for activation of helper t cell and composition for use in the method |
| TW201623616A (zh) | 2010-10-05 | 2016-07-01 | 癌免疫研究所股份有限公司 | 用於活化細胞毒性ｔ細胞的方法及組成物，及用於細胞毒性ｔ細胞之活化誘導物 |
| WO2013106834A2 (fr) | 2012-01-13 | 2013-07-18 | Memorial Sloan Kettering Cancer Center | Peptides wt-1 immunogènes et leurs procédés d'utilisation |
| CA2892660C (fr) | 2012-12-17 | 2022-02-15 | Otsuka Pharmaceutical Co., Ltd. | Procede pour activer des lymphocytes t auxiliaires |
| LT2945647T (lt) | 2013-01-15 | 2021-02-25 | Memorial Sloan Kettering Cancer Center | Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| BR112017012381A2 (pt) * | 2014-12-11 | 2018-06-19 | International Institute Of Cancer Immunology, Inc. | imunoterapia para doença angiogênica |
| CN111647066B (zh) * | 2020-07-01 | 2020-12-18 | 维肽瀛(上海)生物技术有限公司 | Wt1多肽肿瘤抑制剂 |
| CA3228494A1 (fr) | 2021-08-12 | 2023-02-16 | International Institute Of Cancer Immunology, Inc. | Composition pharmaceutique et procede de traitement ou de prevention du cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5726288A (en) | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
| DE69940264D1 (de) | 1998-07-31 | 2009-02-26 | Int Inst Cancer Immunology Inc | Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1 |
| US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| EP1117687B1 (fr) | 1998-09-30 | 2008-06-25 | Corixa Corporation | Compositions et methodes relatives a une immunotherapie specifique du wt1 |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| EP1261711A2 (fr) | 2000-02-22 | 2002-12-04 | Corixa Corporation | Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin |
| ATE383375T1 (de) | 2001-03-22 | 2008-01-15 | Int Inst Cancer Immunology Inc | Wti-modifiziertes peptid |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| JP4229832B2 (ja) | 2001-06-29 | 2009-02-25 | 忠範 真弓 | 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原とカチオン性リポソームとを含んで成る癌ワクチン |
| EP1447091A4 (fr) | 2001-09-28 | 2008-02-13 | Institute Of Can International | Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes |
| EP1447092A4 (fr) | 2001-09-28 | 2007-07-11 | Haruo Sugiyama | Methodes d'induction de lymphocytes t specifiques d'un antigene |
| CN100408683C (zh) | 2002-06-12 | 2008-08-06 | 株式会社国际癌症免疫研究所 | Hla-a24限制性癌抗原肽 |
| AU2003262094A1 (en) | 2002-09-12 | 2004-04-30 | Haruo Sugiyama | Cancer antigen peptide preparation |
| JP4480580B2 (ja) | 2002-09-20 | 2010-06-16 | 株式会社癌免疫研究所 | Ｗｔ１置換型ペプチド |
| ES2332590T3 (es) | 2003-01-15 | 2010-02-09 | International Institute Of Cancer Immunology, Inc. | Dimero peptidico. |
| EP1640458B1 (fr) | 2003-06-27 | 2011-12-28 | International Institute of Cancer Immunology, Inc. | Procede de selection de patients aptes pour le vaccin wt1 |
| ES2378264T3 (es) | 2003-11-05 | 2012-04-10 | International Institute Of Cancer Immunology, Inc. | Péptido antigénico de unión a HLA-DR derivado de WT1 |
| DK2186896T3 (en) | 2004-03-31 | 2015-12-21 | Int Inst Cancer Immunology Inc | Cancer antigen peptides derived from WT1 |
| JP4719876B2 (ja) | 2005-04-04 | 2011-07-06 | 国立大学法人愛媛大学 | Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド |
| CA2900087C (fr) | 2005-10-17 | 2024-02-13 | Sloan Kettering Institute For Cancer Research | Peptides de liaison wt1 hla de classe ii, compositions et methodes associees comprenant ces peptides |
| ES2352855T3 (es) | 2005-11-30 | 2011-02-23 | International Institute Of Cancer Immunology, Inc. | Nuevos compuestos peptídicos del tumor de wilms. |
| US7420880B2 (en) | 2005-12-29 | 2008-09-02 | Timex Group B.V. | Multimode electronic device with calibrating/setting mechanism |
| AU2007218649B2 (en) | 2006-02-22 | 2013-01-10 | International Institute Of Cancer Immunology, Inc. | HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
| US9265816B2 (en) * | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
| ES2556831T3 (es) * | 2006-12-28 | 2016-01-20 | International Institute Of Cancer Immunology, Inc. | Péptido de WT1 restringido a HLA-A*1101 y composiciones farmacéuticas que contienen al mismo |
| NZ578721A (en) * | 2007-02-27 | 2012-04-27 | Int Inst Cancer Immunology Inc | Method for activation of helper t cell and composition for use in the method |
| WO2008108257A1 (fr) | 2007-03-05 | 2008-09-12 | International Institute Of Cancer Immunology, Inc. | Gène du récepteur des lymphocytes t spécifique d'un antigène de cancer, peptide codé par le gène et leur utilisation |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| TW201623616A (zh) * | 2010-10-05 | 2016-07-01 | 癌免疫研究所股份有限公司 | 用於活化細胞毒性ｔ細胞的方法及組成物，及用於細胞毒性ｔ細胞之活化誘導物 |
| CA2892660C (fr) | 2012-12-17 | 2022-02-15 | Otsuka Pharmaceutical Co., Ltd. | Procede pour activer des lymphocytes t auxiliaires |
-
2013
- 2013-12-16 CA CA2892660A patent/CA2892660C/fr active Active
- 2013-12-16 KR KR1020157018417A patent/KR102158225B1/ko active IP Right Grant
- 2013-12-16 BR BR112015013697A patent/BR112015013697A2/pt not_active IP Right Cessation
- 2013-12-16 TW TW102146368A patent/TWI646970B/zh active
- 2013-12-16 US US14/652,298 patent/US9833493B2/en active Active
- 2013-12-16 CN CN201380065804.3A patent/CN104995203B/zh active Active
- 2013-12-16 NZ NZ708990A patent/NZ708990A/en unknown
- 2013-12-16 JP JP2014553122A patent/JP6530192B2/ja active Active
- 2013-12-16 MY MYPI2015701777A patent/MY175935A/en unknown
- 2013-12-16 WO PCT/JP2013/083580 patent/WO2014098012A1/fr active Application Filing
- 2013-12-16 EA EA201591168A patent/EA201591168A1/ru unknown
- 2013-12-16 AU AU2013365067A patent/AU2013365067B2/en active Active
- 2013-12-16 MX MX2015007745A patent/MX2015007745A/es unknown
- 2013-12-16 CN CN201910520821.0A patent/CN110195040A/zh active Pending
- 2013-12-16 SG SG11201504530VA patent/SG11201504530VA/en unknown
- 2013-12-16 SG SG10201705028WA patent/SG10201705028WA/en unknown
- 2013-12-16 EP EP13864968.6A patent/EP2933261B1/fr active Active
- 2013-12-16 ES ES13864968T patent/ES2805337T3/es active Active
- 2013-12-16 UA UAA201507132A patent/UA118962C2/uk unknown
- 2013-12-16 AR ARP130104756A patent/AR094026A1/es unknown
-
2015
- 2015-05-28 IL IL239056A patent/IL239056A0/en unknown
- 2015-06-16 PH PH12015501361A patent/PH12015501361A1/en unknown
-
2016
- 2016-04-20 HK HK16104510.5A patent/HK1216755A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201591168A1 (ru) | 2016-05-31 |
| HK1216755A1 (zh) | 2016-12-02 |
| KR20150096697A (ko) | 2015-08-25 |
| AU2013365067A1 (en) | 2015-07-09 |
| IL239056A0 (en) | 2015-07-30 |
| CN110195040A (zh) | 2019-09-03 |
| AR094026A1 (es) | 2015-07-08 |
| US20150328278A1 (en) | 2015-11-19 |
| KR102158225B1 (ko) | 2020-09-21 |
| WO2014098012A1 (fr) | 2014-06-26 |
| MX2015007745A (es) | 2015-12-15 |
| TWI646970B (zh) | 2019-01-11 |
| EP2933261A4 (fr) | 2016-07-06 |
| CA2892660A1 (fr) | 2014-06-26 |
| CA2892660C (fr) | 2022-02-15 |
| JPWO2014098012A1 (ja) | 2017-01-12 |
| CN104995203A (zh) | 2015-10-21 |
| TW201429487A (zh) | 2014-08-01 |
| SG10201705028WA (en) | 2017-07-28 |
| EP2933261B1 (fr) | 2020-06-10 |
| NZ708990A (en) | 2020-03-27 |
| EP2933261A1 (fr) | 2015-10-21 |
| US9833493B2 (en) | 2017-12-05 |
| ES2805337T3 (es) | 2021-02-11 |
| AU2013365067B2 (en) | 2017-10-05 |
| SG11201504530VA (en) | 2015-07-30 |
| CN104995203B (zh) | 2019-06-28 |
| JP6530192B2 (ja) | 2019-06-12 |
| UA118962C2 (uk) | 2019-04-10 |
| PH12015501361B1 (en) | 2015-09-02 |
| BR112015013697A2 (pt) | 2017-11-14 |
| PH12015501361A1 (en) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY175935A (en) | Method for activating helper t cell | |
| MY170306A (en) | Method for activating helper t cell | |
| CY1122278T1 (el) | Αντι il-36r αντισωματα | |
| CY1121419T1 (el) | Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης | |
| PH12014502010A1 (en) | Bispecific antibodies against human tweak and human il17 and uses thereof | |
| EA201391059A1 (ru) | Композиции для лечения рака и способы их применения | |
| UA115772C2 (uk) | Композиція програмованого нуклеопротеїнового молекулярного комплексу і спосіб модифікування заданої послідовності нуклеїнової кислоти-мішені | |
| EP4297036A3 (fr) | Méthode permettant de prédire la liaison non ciblée d'un peptide qui se lie à un peptide cible présenté par un complexe majeur d'histocompatibilité | |
| EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| TR201903026T4 (tr) | S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari. | |
| MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
| MX2022006304A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
| MX2014004326A (es) | Anticuerpos a cd1d. | |
| MX2015017959A (es) | Composiciones y metodos para inmunoterapia. | |
| UA115321C2 (uk) | Спосіб та комплект для аналізу ahasl генів у рослин | |
| WO2014097318A3 (fr) | Agents pour éliminer des cellules d'initiation tumorale | |
| TR201910413T4 (tr) | Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler. | |
| MY176708A (en) | Peptides | |
| IN2014DN07103A (fr) | ||
| GB201020671D0 (en) | Passive immunotherapy | |
| MY170643A (en) | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | |
| WO2014184683A3 (fr) | Compositions et procédés de ciblage de cellules présentatrices d'antigène | |
| TR201104864A2 (tr) | Deksketoprofen içeren suda çözünebilir formülasyonlar. | |
| TH165802A (th) | วิธีสำหรับการแอคทิเวต เฮลเปอร์ t เซลล์ |